Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muraglitazar in type 2 diabetes
NCT00240383Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2002
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of muraglitazar in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change from baseline in Hemoglobin A1c at 24 weeks. Started May 2002; status: completed.
02
Drugs
muraglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00240383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240383.